Jane Street’s Altimmune ALT Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$174K Sell
56,400
-48,000
-46% -$204K ﹤0.01% 10272
2025
Q4
$377K Buy
104,400
+45,700
+78% +$199K ﹤0.01% 8328
2025
Q3
$221K Buy
58,700
+26,300
+81% +$102K ﹤0.01% 9479
2025
Q2
$125K Buy
32,400
+600
+2% +$3.25K ﹤0.01% 8850
2025
Q1
$159K Sell
31,800
-42,200
-57% -$267K ﹤0.01% 8595
2024
Q4
$534K Buy
74,000
+25,200
+52% +$193K ﹤0.01% 6647
2024
Q3
$300K Sell
48,800
-200
-0.4% -$1.35K ﹤0.01% 8042
2024
Q2
$326K Buy
49,000
+4,700
+11% +$34.7K ﹤0.01% 7677
2024
Q1
$451K Sell
44,300
-44,800
-50% -$456K ﹤0.01% 6849
2023
Q4
$1M Buy
+89,100
New +$372K ﹤0.01% 5551
2023
Q3
Sell
-31,000
Closed -$109K 8556
2023
Q2
$109K Sell
31,000
-135,600
-81% -$609K ﹤0.01% 7967
2023
Q1
$703K Buy
+166,600
New +$1.98M ﹤0.01% 5708
2022
Q4
Sell
-117,800
Closed -$1.5M 9060
2022
Q3
$1.5M Buy
+117,800
New +$1.74M ﹤0.01% 4680
2022
Q1
Sell
-49,100
Closed -$450K 10207
2021
Q4
$450K Sell
49,100
-15,000
-23% -$159K ﹤0.01% 7456
2021
Q3
$725K Sell
64,100
-36,300
-36% -$441K ﹤0.01% 6566
2021
Q2
$989K Buy
100,400
+17,000
+20% +$232K ﹤0.01% 5871
2021
Q1
$1.18M Buy
83,400
+6,200
+8% +$100K ﹤0.01% 5141
2020
Q4
$871K Buy
+77,200
New +$910K ﹤0.01% 4885

Other funds holding ALT

Jane Street's ALT Position: Q1 2026 in Review

Jane Street sold out of Altimmune (ALT) in Q1 2026, closing a stake of 1,783,950 shares — an estimated $7.57M sold.

Jane Street first reported a position in ALT in Q2 2013 and held it in 22 quarters. The position peaked at $6.53M in Q4 2023. 173 funds tracked by Wall St. Rank hold ALT as of Q1 2026.

  • Jane Street reported no remaining Altimmune position as of Q1 2026 after selling out during the quarter.
  • Jane Street sold 1,783,950 Altimmune shares in Q1 2026, an estimated $7.57M.
  • Jane Street first reported a position in Altimmune in Q2 2013 and held it in 22 quarters.
  • Jane Street's Altimmune position peaked at $6.53M in Q4 2023.
  • 173 funds tracked by Wall St. Rank held Altimmune as of Q1 2026.

Based on Jane Street's 13F filing for Q1 2026, filed 12 May 2026.